Northern General and Royal Hallamshire hospitals, part of Sheffield Teaching hospitals, has successfully finalized a two-part evaluation study of Hemcheck’s products (v-Test) at the department of coagulation. This formal evaluation confirm that the tests does not interfere with subsequent coagulation testing and that the performance of Hemcheck’s products is very high.
The first part of the study was to confirm that the usage of the v-Test does not alter the results of important analyses performed on blood samples in citrate tubes analysed on Sysmex CS5100, which included Prothrombin Time, APTT, Fibrinogen, Thrombin Time, DDimer.
The second part of the study was to compare the results, in over 800 samples, of Hemcheck’s system and the laboratory’s Sysmex CS5100 system as well as visual inspection, as the reference methods.
The conclusions are that Hemcheck’s system does not interfere with the included subsequent analyses and has good performance and correlation with the reference method, while being quick and easy to use.
–This is additional positive news as it gives more evidence on the performance and the value of our system, in the field of coagulation. We look forward to continuing discussions with Sheffield Teaching hospitals on potential next steps, says Joen Averstad, CEO of Hemcheck.
– I am very pleased with the study and the interesting results. The Hemcheck system showed good performance and I believe it can be an important tool especially when used at the point of care, says Dr Steve Kitchen, Scientific Director of the UK NEQAS for Blood Coagulation and Lead clinical scientist Department of Coagulation, and responsible for the study.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About Sheffield Teaching hospitals
Sheffield Teaching Hospitals NHS Foundation Trust is one of the UK’s largest, busiest, and most successful NHS foundation trusts. They primarily provide a full range of hospital and community services for people in Sheffield. They include five teaching hospitals including: Northern General Hospital; Royal Hallamshire Hospital; Charles Clifford Dental Hospital; Weston Park Cancer Hospital; Jessop Wing Maternity Hospital
Read more at: https://www.sth.nhs.uk/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolyzed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolyzed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.